title: Determining the optimal treatment for metastatic castration-resistant prostate cancer: age should not be a factor.
authors.affiliation: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
authors.forename: Daniel L
authors.initials: DL
authors.lastname: Suzman
authors.affiliation: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. Electronic address: eisenma@jhmi.edu.
authors.forename: Mario A
authors.initials: MA
authors.lastname: Eisenberger
mesh_terms: D000069501:Abiraterone Acetate; D000730:Androstadienes / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000473:pathology*; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors*
chemical_list: D000730:Androstadienes; D013254:Steroid 17-alpha-Hydroxylase; D000069501:Abiraterone Acetate